Skip to main content
Equibles
FTH logo

FTH · Faeth Therapeutics, Inc.

Track FTH — free

Use FTH with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about FTH

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$32.34 +3.79 (+13.27%) At close · Aug 14
Going-concern doubt — cleared Aug 4, 2026

The latest filing no longer states the doubt (first flagged May 15, 2026).

View the 10-Q filed Aug 4, 2026
Market Cap
$835.68M
Shares
25.84M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$32.34 Open$29.95 Day$28.73–33.20 52W close$7.50–36.16 Avg vol 30d288K Short int816K · 3.2% float · 2.8d Short vol68% Last earningsAug 5, 2025 DataJun 2025–Aug 2026 Filing10-Q · Aug 4

Raw chart and full-history price indicators begin at the captured split on Jun 17, 2025; bars on opposite sides are not compared.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 4, 2026

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Strong Buy Momentum Strong Sentiment Very Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 14.3 · calm Equity put/call 0.52
Technical
price trend
Strong Buy
50 / 200-day cross No cross
Price vs 200-day avg +63%
above
Price vs 50-day avg +32%
above
RSI (14) 64
neutral
MACD trend Positive
52-week position 87%
near high
Momentum
relative strength
Strong
1-month return +25%
trailing
6-month return −1%
trailing
YTD return +203%
this year
Relative strength −15%
vs S&P · 6-mo
Sentiment
smart money
Very Bullish
Trend (MA cross) No cross
50d $25 › 200d $20 — 50d above 200d
Institutional flow Accumulating
+50% holders QoQ · +22 funds added
Insider flow Accumulating
Net +$187.7K over 90 days · 50% sells
Short interest Falling
3.16% of float · ▼ -8.4% MoM · 2.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
45 holders — near 1-yr high, broad support
Squeeze score 66
elevated · 0–100
Fundamentals
Strong
EPS growth +30%
Y/Y
Free cash flow $-20.5M
Balance sheet $8.1M
net cash
Quant / Vol
risk profile
Very High
Volatility 223%
annualized · 1-yr
Max drawdown −69%
past year
ATR 10.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Buy
0 · 2 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+63% Bullish
Price vs 50-day avg
+32% Bullish
RSI (14)
64 Neutral
MACD trend
Positive Bullish
52-week position
87% Bullish
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross) No cross
50d $25 › 200d $20 — 50d above 200d
Institutional flow Accumulating
+50% holders QoQ · +22 funds added
Insider flow Accumulating
Net +$187.7K over 90 days · 50% sells
Short interest Falling
3.16% of float · ▼ -8.4% MoM · 2.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
45 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $8 Now $32 · 87% Range high $36
vs 200-day avg +63% vs 50-day avg +32%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
FTH
Faeth Therapeutics, Inc.
this stock
$835.68M +203.1% — — 3.2%
ONC
BeOne Medicines Ltd.
 $513.62B +14.4% +22179.2% 789.7 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $128.19B +11.6% +46.2% 29.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $82.72B +4.1% +20.8% 19.9 3.3%
ARGX
Argenx SE
 $52.94B +1.2% — — 2.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
45
% held
54.5%
Net QoQ
+11.9M sh
Top holder
SUVRETTA CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
9
View
Short & Settlement
Short Interest Falling
Shares short
815.6K
Days to cover
2.8d
Change
-74.7K sh
View
Short Volume
Short vol %
68%
As of
Aug 14, 2026
Short Total
View
Fails to Deliver
FTD shares
2.7K
Value
$96.1K
As of
Jul 13, 2026
View
Off-Exchange
Off-exchange %
38.4%
Week of
Jul 6, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$187.7K
Buyers / Sellers
2 / 2
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-21.1M
EPS diluted
$-16.72
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 4, 2026
This year
19
View
Proposed Sales
Value
$3.6M
Shares
130.1K
Filed
Aug 11, 2026
View
Exempt Offerings
Offering
$348.9M
Filed
Mar 4, 2026
View
Earnings & Events
Earnings Calls
Last call
Apr 16, 2026
View

Performance

Raw-price comparisons begin at the captured split on Jun 17, 2025; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
FTH +32.6% +25.0% -0.9% +18.7% +203.1%
SPY +0.4% +4.5% +13.8% +3.9% +13.9%
vs SPY +32.2% +20.6% -14.7% +14.8% +189.2%
Key facts CIK 1829802 CUSIP 81728A207 13F (30d) 49 filings 47 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)